Of the KRAS mutations detected, 17% were outside of codons 12 and 13.
KRAS的基因突变中，我们检测到17%是位于12号和13号密码子以外的。
About 30 percent of human lung cancer patients have mutations in Kras.
大约30%的人类肺癌病人有Kras突变。
Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival?
【译】在转移性结直肠癌影响总生存期KRAS测试吗？
About 40% of these patients have a KRAS gene mutation, and respond poorly to such antibodies.
约40%患者有KRAS基因突变而对这类抗体反应很差。
KRAs are the limited number of areas in which satisfactory results will ensure the achievement of the business goals.
关键结果领域是一组关键结果领域是组确保达成业务目标的、不可或缺的、必须取得满意结果的领域。
The site, located in the Kras region (literally meaning karst), is one of the most famous in the world for the study of karstic phenomena.
斯科契扬溶洞位于克拉斯地区(原文意为喀斯特)，这里是世界上研究喀斯特现象的著名地点之一。
The combination accelerated the development of lung cancers that carried a mutation in the gene KRAS - a common feature of many human lung cancers.
结果发现两种物质的联合加速了肺癌的进展，肺癌中存在KRAS基因突变，即人类肺癌中一种常见的特征。
Two paired neuroendocrine carcinomas and adjacent adenomas showed identical KRAS mutations, but only PIK3CA mutations in neuroendocrine carcinomas.
神经内分泌癌及相邻的腺瘤配对研究，表明具有相同的KRAS突变，但神经内分泌癌中仅见pik3ca突变。
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance).
【译】KRAS基因密码子12和13与无病生存的野生型BRAF的II I期结肠癌辅助化疗试验从一个突变(n0147联盟)。
Conclusion: These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetuximab.
结论：这些结果证实了：KRAS突变对于转移性CRC患者使用西妥昔单抗治疗时对西妥昔单抗耐药情况和生存期具有很高的预测价值。
Objective: To evaluate the feasibility and sensitivity of detecting the mutations of KRAS in colorectal carcinoma patients with high resolution melting curve analysis.
目的：探讨利用新的高分辨率熔解曲线分析法检测结直肠癌中KRAS基因突变的可行性。
BRAF and KRAS mutant traditional serrated adenomas are morphologically related but biologically disparate polyps with distinctive clinicopathological and molecular features.
BRAF和KRAS突变传统锯齿状腺瘤为形态学相关、但生物学上不同的息肉，具有不同的临床病理学和分子特征。
These results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner.
这些发现提示，KRAS的突变是获得性EGFR阻滞治疗抵抗的媒介；而且，这些突变可以用非侵入的方法检测到。
KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.
KRAS基因突变在恶性肿瘤组织中频发，可预测非小细胞肺癌分子靶向治疗的疗效和预后，针对RAS基因的分子抑制剂研究仍处于初级阶段。
We found that 9 out of 24 (38%) patients whose tumours were initially KRAS wild type developed detectable mutations in KRAS in their sera, three of which developed multiple different KRAS mutations.
结果发现，在24名治疗前KRAS为野生型的患者中有9名(38%)患者的血清检测出突变型KRAS。其中3名的突变为多位点的不同突变。
We found that 9 out of 24 (38%) patients whose tumours were initially KRAS wild type developed detectable mutations in KRAS in their sera, three of which developed multiple different KRAS mutations.
结果发现，在24名治疗前KRAS为野生型的患者中有9名(38%)患者的血清检测出突变型KRAS。其中3名的突变为多位点的不同突变。
应用推荐